Novo Nordisk A/S (NVO) Total Return CAGR:-40.89%(TTM)
Over the latest trailing 12-month period, Novo Nordisk A/S (NVO)'s total return cagr is -40.89%. The comparable SPY value is +25.93%. Year-to-date total return is -11.45%. Total return includes price appreciation and reinvested dividends.
Over longer horizons, Novo Nordisk A/S's Total Return CAGR averages -16.45% over 3 years and 2.95% over 5 years. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of Novo Nordisk A/S's investment performance.
NVO Total Return CAGR Chart
Novo Nordisk A/S (NVO)
NVO Quarterly Total Return (YoY)
Total Return Index growth vs the same quarter one year earlier, last 20 quarters.
NVO Total Return CAGR History
| Year | Start Total Return | End Total Return | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2026 | 11846.36 | 10489.51 | -1356.86 | -11.45% | -11.45% |
| 2025 | 19491.89 | 11846.36 | -7645.53 | -39.22% | -39.22% |
| 2024 | 23184.66 | 19491.89 | -3692.77 | -15.93% | -15.93% |
| 2023 | 14977.86 | 23184.66 | +8206.80 | +54.79% | +54.79% |
| 2022 | 12211.39 | 14977.86 | +2766.47 | +22.65% | +22.65% |
| 2021 | 7472.65 | 12211.39 | +4738.74 | +63.41% | +63.41% |
| 2020 | 6061.00 | 7472.65 | +1411.64 | +23.29% | +23.29% |
| 2019 | 4711.55 | 6061.00 | +1349.45 | +28.64% | +28.64% |
| 2018 | 5346.82 | 4711.55 | -635.27 | -11.88% | -11.88% |
| 2017 | 3464.87 | 5346.82 | +1881.96 | +54.32% | +54.32% |
| 2016 | 5461.76 | 3464.87 | -1996.89 | -36.56% | -36.56% |
| 2015 | 3920.34 | 5461.76 | +1541.42 | +39.32% | +39.32% |
| 2014 | 3360.26 | 3920.34 | +560.08 | +16.67% | +16.67% |
| 2013 | 2911.48 | 3360.26 | +448.78 | +15.41% | +15.41% |
| 2012 | 2021.12 | 2911.48 | +890.35 | +44.05% | +44.05% |
| 2011 | 1944.04 | 2021.12 | +77.09 | +3.97% | +3.97% |
| 2010 | 1084.41 | 1944.04 | +859.63 | +79.27% | +79.27% |
| 2009 | 852.21 | 1084.41 | +232.20 | +27.25% | +27.25% |
| 2008 | 1061.48 | 852.21 | -209.27 | -19.71% | -19.71% |
| 2007 | 673.73 | 1061.48 | +387.75 | +57.55% | +57.55% |
| 2006 | 445.61 | 673.73 | +228.12 | +51.19% | +51.19% |
| 2005 | 423.36 | 445.61 | +22.25 | +5.26% | +5.26% |
| 2004 | 315.30 | 423.36 | +108.07 | +34.27% | +34.27% |
| 2003 | 219.58 | 315.30 | +95.72 | +43.59% | +43.59% |
| 2002 | 301.26 | 219.58 | -81.68 | -27.11% | -27.11% |
| 2001 | 263.20 | 301.26 | +38.06 | +14.46% | +14.46% |
| 2000 | 190.14 | 263.20 | +73.06 | +38.42% | +38.42% |
| 1999 | 193.87 | 190.14 | -3.73 | -1.92% | -1.92% |
| 1998 | 209.11 | 193.87 | -15.24 | -7.29% | -7.29% |
| 1997 | 135.02 | 209.11 | +74.09 | +54.88% | +54.88% |
Quarterly Total Return: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 10,490 | +22.4% | -33.5% |
| Q1 2026 | 8,573 | -28.1% | -47.3% |
| Q4 2025 | 11,926 | -7.7% | -49.1% |
| Q3 2025 | 12,922 | -18.1% | -57.7% |
| Q2 2025 | 15,780 | -2.9% | -50.4% |
| Q1 2025 | 16,254 | -30.7% | -43.9% |
| Q4 2024 | 23,439 | -23.3% | +1.9% |
| Q3 2024 | 30,563 | -3.8% | +49.6% |
| Q2 2024 | 31,783 | +9.7% | +79.1% |
| Q1 2024 | 28,984 | +26.0% | +78.5% |
| Q4 2023 | 23,012 | +12.7% | +53.8% |
| Q3 2023 | 20,424 | +15.1% | +85.7% |
| Q2 2023 | 17,741 | +9.3% | +48.8% |
| Q1 2023 | 16,235 | +8.5% | +38.5% |
| Q4 2022 | 14,962 | +36.1% | +24.9% |
| Q3 2022 | 10,996 | -7.8% | -0.0% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar